Journal Facts

Journal
BoneKEy Knowledge Environment
ISSN
1533-4368
Volume
Year
2003

Article Facts

Title
Clinical papers: November 2002 selections
DOI
10.1138/2003079
Author

Online Date
03/19/2003

Article Links

BoneKEy-Osteovision | Not To Be Missed

Clinical papers: November 2002 selections


DOI:10.1138/2003079

Bone modeling and remodeling

◆ Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest. 2002 Apr;109(7):915–21.

◆ Burr DB, Robling AG, Turner CH. Effects of biomechanical stress on bones in animals. Bone. 2002 May;30(5):781–6.

◆ Ehrlich PJ, Lanyon LE. Mechanical strain and bone cell function: a review. Osteoporos Int. 2002 Sep;13(9):688–700.

◆ Miao D, He B, Karaplis AC, Goltzman D. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest. 2002 May;109(9):1173–82.

◆ Parfitt AM. Misconceptions (1): epiphyseal fusion causes cessation of growth. Bone. 2002 Feb;30(2):337–9.

◆ Power J, Loveridge N, Rushton N, Parker M, Reeve J. Osteocyte density in aging subjects is enhanced in bone adjacent to remodeling haversian systems. Bone. 2002 Jun;30(6):859–65.

◆ Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int. 2002;13(2):97–104.

◆ Seeman E. An exercise in geometry. J Bone Miner Res. 2002 Mar;17(3):373–80.

◆ Verborgt O, Tatton NA, Majeska RJ, Schaffler MB. Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation? J Bone Miner Res.2002 May;17(5):907–14.

◆ Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002 Apr;109(8):1041–8.

Diagnosis

◆ Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002 Jun 1;359(9321):1929–36.

Epidemiology

◆ Bilezikian JP. Sex steroids, mice, and men: when androgens and estrogens get very close to each other. J Bone Miner Res. 2002 Apr;17(4):563–6.

◆ Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002 May 18;359(9319):1761–7.

◆ Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2002 Jun;17(6):1051–6.

Genetics

◆ Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002 May 16;346(20):1513–21.

◆ Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab. 2002 Jun;87(6):2460–6.

Pathophysiology

◆ Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002 Jun;109(12):1625–33.

◆ Khosla S, Melton LJ.3rd, Riggs BL. Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab. 2002 Apr;87(4):1443–50.

◆ Robling AG, Hinant FM, Burr DB, Turner CH. Improved bone structure and strength after long-term mechanical loading is greatest if loading is separated into short bouts. J Bone Miner Res. 2002 Aug;17(8):1545–54.

◆ Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002 Aug;283(2):E284–94.

◆ Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002 May 25;359(9320):1841–50.

Treatment and drug effects

◆ Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002 Feb 20;287(7):847–57.

◆ Boivin G, Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int. 2002 Jun;70(6):503–11.

◆ Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res. 2002 Jul;17(7):1139–47.

◆ Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002 Mar;13(3):257–64.

◆ Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002 Jun 8;359(9322):2018–26.

◆ Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int. 2002 May;13(5):349–52.

◆ Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002 Feb 6;287(5):591–7.

◆ Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002 Aug 20;137(4):273–84.

◆ Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002 Mar;87(3):985–92.

◆ Kanis JA, Oden A, Johnell O, Caulin F, Bone H, Alexandre JM, Abadie E, Lekkerkerker F. Uncertain future of trials in osteoporosis. Osteoporos Int. 2002;13(6):443–9.

◆ Marcus R, Wong M, Heath H.3rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002 Feb;23(1):16–37.

◆ Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002 May;87(5):2060–6.

◆ Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002 Jan;87(1):16–23.

◆ Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002 Aug 21;288(7):872–81.

◆ Rubin MR, Cosman F, Lindsay R, Bilezikian JP. The anabolic effects of parathyroid hormone. Osteoporos Int. 2002;13(4):267–77.

◆ Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc. 2002 Mar;77(3):262–70.

Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.